NADAC acquisition cost data for GENTAMICIN 0.1% OINTMENT. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00713068231 | $1.15 | 2022-12-21 | Rx |
| 45802004611 | $1.15 | 2022-12-21 | Rx |
| 52565009030 | $1.15 | 2022-12-21 | Rx |
| 00713068215 | $1.22 | 2022-12-21 | Rx |
| 45802004635 | $1.22 | 2022-12-21 | Rx |
| 52565009015 | $1.22 | 2022-12-21 | Rx |
| 00713068231 | $1.15 | 2022-12-21 | Rx |
| 45802004611 | $1.15 | 2022-12-21 | Rx |
| 52565009030 | $1.15 | 2022-12-21 | Rx |
| 00713068215 | $1.22 | 2022-12-21 | Rx |
Generic: Gentamicin Sulfate/PF | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $30.4K | 381 | 116 | $0.1517 |
| 2020 | $32.0K | 416 | 109 | $0.2502 |
| 2021 | $18.9K | 226 | 80 | $0.6676 |
| 2022 | $42.5K | 731 | 182 | $0.5094 |
| 2023 | $32.1K | 596 | 89 | $0.9759 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $2.1M | 63,712 | 43,884 |
| California | $1.2M | 34,998 | 22,622 |
| New York | $962.1K | 25,419 | 15,529 |
| Texas | $932.2K | 27,326 | 18,057 |
| Ohio | $556.5K | 16,343 | 10,041 |
| Illinois | $499.3K | 13,824 | 8,692 |
| Pennsylvania | $445.8K | 13,466 | 8,989 |
| Michigan | $441.8K | 14,410 | 8,881 |
| New Jersey | $392.4K | 10,935 | 7,526 |
| Puerto Rico | $373.7K | 10,539 | 7,900 |
| North Carolina | $345.4K | 10,538 | 7,059 |
| Missouri | $340.9K | 8,703 | 5,315 |
| Tennessee | $302.2K | 9,987 | 6,809 |
| Georgia | $297.8K | 11,242 | 7,919 |
| Virginia | $236.6K | 7,180 | 4,634 |
| Indiana | $235.3K | 7,620 | 4,557 |
| Kentucky | $196.3K | 6,894 | 4,141 |
| Mississippi | $193.1K | 6,117 | 4,179 |
| Maryland | $184.5K | 4,867 | 3,261 |
| Alabama | $183.5K | 7,813 | 5,710 |
| Arizona | $179.1K | 6,246 | 4,601 |
| Louisiana | $178.2K | 5,243 | 3,708 |
| Connecticut | $175.3K | 4,872 | 3,402 |
| Wisconsin | $163.8K | 4,681 | 2,958 |
| Oklahoma | $154.9K | 4,345 | 2,754 |
| Massachusetts | $151.5K | 4,140 | 2,465 |
| Kansas | $149.9K | 4,263 | 2,700 |
| Iowa | $135.4K | 4,747 | 2,704 |
| Minnesota | $132.5K | 3,422 | 1,929 |
| South Carolina | $131.3K | 4,776 | 3,409 |
| Washington | $128.8K | 3,566 | 2,290 |
| Nevada | $121.7K | 3,282 | 2,084 |
| Arkansas | $117.2K | 3,970 | 2,758 |
| Hawaii | $89.1K | 2,325 | 1,497 |
| Colorado | $79.9K | 2,466 | 1,695 |
| Utah | $68.5K | 2,121 | 1,001 |
| Oregon | $59.7K | 1,715 | 1,094 |
| West Virginia | $51.4K | 2,059 | 1,351 |
| Idaho | $44.5K | 1,287 | 811 |
| New Mexico | $42.7K | 1,423 | 980 |
| Nebraska | $35.1K | 1,150 | 813 |
| Delaware | $31.8K | 861 | 566 |
| Rhode Island | $24.8K | 860 | 521 |
| South Dakota | $22.8K | 655 | 458 |
| District of Columbia | $17.7K | 451 | 271 |
| Maine | $17.3K | 574 | 353 |
| New Hampshire | $16.8K | 587 | 418 |
| North Dakota | $16.3K | 599 | 424 |
| Vermont | $12.9K | 320 | 180 |
| Montana | $10.8K | 585 | 387 |
| New York | $10.3K | 158 | 11 |
| Wyoming | $8.2K | 428 | 254 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.